New Research and Case Studies Demonstrate Effectiveness of Machine Learning-Based Platforms for Adaptive Clinical Trial Design and Analysis BOSTON, Sept.…
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical…
NORCROSS, Ga., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target…
10 patients have been treated to date with azer-cel in the Phase 1b diffuse large B-cell lymphoma (DLBCL) trial Cohort…
SHANGHAI, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading…
LOS ANGELES, Aug. 29, 2024 (GLOBE NEWSWIRE) -- With Blood Cancer Awareness Month coming up this September, the International Myeloma…
R&D Discussion in New York City to Review IL-12’s Potential to Treat Ovarian Cancer Program Features Ovarian Cancer Thought Leaders,…
PASADENA, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”),…
SOUTH SAN FRANCISCO, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), today announced its President and Chief…
Professor Peled is the Director of the Oncology Department at the Shaare Zedek Medical Center, Jerusalem, Israel, and the head…